Matt Phipps
Stock Analyst at William Blair
(0.07)
# 4,195
Out of 4,834 analysts
18
Total ratings
14.29%
Success rate
-39.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $0.79 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $8.14 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $19.08 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $13.59 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $8.51 | - | 1 | Nov 5, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | n/a | $5.68 | - | 1 | Sep 30, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $7.19 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $44.12 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $4.18 | - | 2 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $22.62 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.50 | - | 1 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.55 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.85 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $120.37 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $40.40 | - | 1 | Apr 8, 2021 |
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.79
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.14
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $19.08
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $13.59
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.51
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.68
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.19
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $44.12
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.18
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $22.62
Upside: -
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.50
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.55
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.85
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $120.37
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $40.40
Upside: -